Skip Nav Destination
Issues
1 March 2011
-
Cover Image
Cover Image
EGFR-overexpressing A431 cells were transfected with PolyIC/MPPE at 0.1 mcg/mL, 24 hours later, 500,000 PBMCs per well were added to the cancer cells and coincubated for another 24 hours. Apoptotic cells (red fluorescence) were visualized using an Annexin-V-Biotin kit. To distinguish tumor cells from PBMCs, tumor cells were labeled with FITC-conjugated EGFR antibody (green fluorescence). Cells were visualized with a fluorescent microscope and photographed using a digital camera. For further details, please see Shir and coworkers on page 1033 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
CCR New Strategies
Molecular Pathways
Cancer Therapy: Preclinical
GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
Aidan G. Gilmartin; Maureen R. Bleam; Arthur Groy; Katherine G. Moss; Elisabeth A. Minthorn; Swarupa G. Kulkarni; Cynthia M. Rominger; Symon Erskine; Kelly E. Fisher; Jingsong Yang; Francesca Zappacosta; Roland Annan; David Sutton; Sylvie G. Laquerre
Specifically Targeting Angiopoietin-2 Inhibits Angiogenesis, Tie2-Expressing Monocyte Infiltration, and Tumor Growth
Hanhua Huang; Jing-Yu Lai; Janet Do; Dingguo Liu; Lingna Li; Joselyn Del Rosario; Venkata R. Doppalapudi; Steven Pirie-Shepherd; Nancy Levin; Curt Bradshaw; Gary Woodnutt; Rodney Lappe; Abhijit Bhat
FKBPL and Peptide Derivatives: Novel Biological Agents That Inhibit Angiogenesis by a CD44-Dependent Mechanism
Andrea Valentine; Martin O'Rourke; Anita Yakkundi; Jenny Worthington; Michelle Hookham; Roy Bicknell; Helen O. McCarthy; Keeva McClelland; Lynn McCallum; Hayder Dyer; Hayley McKeen; David J. J. Waugh; Jennifer Roberts; Joanne McGregor; Graham Cotton; Iain James; Timothy Harrison; David G. Hirst; Tracy Robson
Imaging, Diagnosis, Prognosis
Prostate Cancer Predisposition Loci and Risk of Metastatic Disease and Prostate Cancer Recurrence
Jiyoung Ahn; Adam S. Kibel; Jong Y. Park; Timothy R. Rebbeck; Hanna Rennert; Janet L. Stanford; Elaine A. Ostrander; Stephen Chanock; Ming-Hsi Wang; Rama D. Mittal; William B. Isaacs; Elizabeth A. Platz; Richard B. Hayes
Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer
Ana M. Gonzalez-Angulo; Kirsten M. Timms; Shuying Liu; Huiqin Chen; Jennifer K. Litton; Jennifer Potter; Jerry S. Lanchbury; Katherine Stemke-Hale; Bryan T. Hennessy; Banu K. Arun; Gabriel N. Hortobagyi; Kim-Anh Do; Gordon B. Mills; Funda Meric-Bernstam
Engrailed-2 (EN2): A Tumor Specific Urinary Biomarker for the Early Diagnosis of Prostate Cancer
Richard Morgan; Angela Boxall; Aagna Bhatt; Michael Bailey; Richard Hindley; Stephen Langley; Hayley C. Whitaker; David E. Neal; Mohammed Ismail; Hamish Whitaker; Nicola Annels; Agnieszka Michael; Hardev Pandha
Imaging Colon Cancer Response Following Treatment with AZD1152: A Preclinical Analysis of [18F]Fluoro-2-deoxyglucose and 3′-deoxy-3′-[18F]Fluorothymidine Imaging
Maxim A. Moroz; Tatiana Kochetkov; Shangde Cai; Jiyuan Wu; Mikhail Shamis; Jayasree Nair; Elisa de Stanchina; Inna Serganova; Gary K. Schwartz; Debabrata Banerjee; Joseph R. Bertino; Ronald G. Blasberg
KPNA2 Expression Is an Independent Adverse Predictor of Biochemical Recurrence after Radical Prostatectomy
Ashkan Mortezavi; Thomas Hermanns; Hans-Helge Seifert; Martin K. Baumgartner; Maurizio Provenzano; Tullio Sulser; Maximilian Burger; Matteo Montani; Kristian Ikenberg; Ferdinand Hofstädter; Arndt Hartmann; Rolf Jaggi; Holger Moch; Glen Kristiansen; Peter J. Wild
KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer
Jeanne Tie; Lara Lipton; Jayesh Desai; Peter Gibbs; Robert N. Jorissen; Michael Christie; Katharine J. Drummond; Benjamin N.J. Thomson; Valery Usatoff; Peter M. Evans; Adrian W. Pick; Simon Knight; Peter W.G. Carne; Roger Berry; Adrian Polglase; Paul McMurrick; Qi Zhao; Dana Busam; Robert L. Strausberg; Enric Domingo; Ian P.M. Tomlinson; Rachel Midgley; David Kerr; Oliver M. Sieber
Cancer Therapy: Clinical
Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors
Pasi A. Jänne; David S. Boss; D. Ross Camidge; Carolyn D. Britten; Jeffrey A. Engelman; Edward B. Garon; Feng Guo; Steven Wong; Jane Liang; Stephen Letrent; Robert Millham; Ian Taylor; S. Gail Eckhardt; Jan H.M. Schellens
A Phase I Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias
Jeffrey E. Lancet; Vu H. Duong; Elliott F. Winton; Robert K. Stuart; Michelle Burton; Shumin Zhang; Christopher Cubitt; Michelle A. Blaskovich; John J. Wright; Said Sebti; Daniel M. Sullivan
Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study
C. Kent Osborne; Patrick Neven; Luc Y. Dirix; John R. Mackey; Jean Robert; Craig Underhill; Rachel Schiff; Carolina Gutierrez; Ilenia Migliaccio; Valsamo K. Anagnostou; David L. Rimm; Patrick Magill; Mark Sellers
Predictive Biomarkers and Personalized Medicine
Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations
Rafael Rosell; Miguel Angel Molina; Carlota Costa; Sara Simonetti; Ana Gimenez-Capitan; Jordi Bertran-Alamillo; Clara Mayo; Teresa Moran; Pedro Mendez; Felipe Cardenal; Dolores Isla; Mariano Provencio; Manuel Cobo; Amelia Insa; Rosario Garcia-Campelo; Noemi Reguart; Margarita Majem; Santiago Viteri; Enric Carcereny; Ruth Porta; Bartomeu Massuti; Cristina Queralt; Itziar de Aguirre; Jose Miguel Sanchez; Maria Sanchez-Ronco; Jose Luis Mate; Aurelio Ariza; Susana Benlloch; Jose Javier Sanchez; Trever G Bivona; Charles L Sawyers; Miquel Taron
Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay
Maria E. Arcila; Geoffrey R. Oxnard; Khedoudja Nafa; Gregory J. Riely; Stephen B. Solomon; Maureen F. Zakowski; Mark G. Kris; William Pao; Vincent A. Miller; Marc Ladanyi
Evaluation of KRAS Mutations, Angiogenic Biomarkers, and DCE-MRI in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Sorafenib
Ronan J. Kelly; Arun Rajan; Jeremy Force; Ariel Lopez-Chavez; Corrine Keen; Liang Cao; Yunkai Yu; Peter Choyke; Baris Turkbey; Mark Raffeld; Liqiang Xi; Seth M. Steinberg; John J. Wright; Shivaani Kummar; Martin Gutierrez; Giuseppe Giaccone
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.